BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Company News  |  Deals

Amgen, Xencor deal

Xencor granted Amgen an option to license exclusive, worldwide rights to autoimmune candidate Xmab5871. The mAb targeting CD19 and ...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >